Immunohistochemical Detection of Treatment-Related Biomarkers in Urothelial Carcinoma
10.3971/j.issn.1000-8578.2025.25.0282
- VernacularTitle:尿路上皮癌治疗相关生物标志物的免疫组织化学检测进展
- Author:
Miaozi GONG
1
;
Huiying HE
2
Author Information
1. Department of Pathology, Peking University Third Hospital/School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China;Department of Pathology, The University of Hong Kong-Shenzhen Hospital, Shenzhen 518053, China.
2. Department of Pathology, Peking University Third Hospital/School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
- Publication Type:SPECIALFEATURE
- Keywords:
Urothelial carcinoma;
Divergent differentiation/histological subtype;
Biomarker;
Immunohistochemistry
- From:
Cancer Research on Prevention and Treatment
2025;52(10):818-826
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors and antibody–drug conjugates are increasingly incorporated into the clinical management of advanced urothelial carcinoma. The immunohistochemical detection of relevant biomarkers facilitates the selection of individualized precision therapies and supports the prediction of therapeutic efficacy. This review summarizes biomarkers associated with the treatment of urothelial carcinoma and the methodologies and clinical applications of immunohistochemical testing, focusing on the correlation between biomarker expression and the divergent differentiation or histological subtypes of urothelial carcinoma.
